ibuprofen has been researched along with Cardiovascular Stroke in 63 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients with symptomatic pericarditis were treated with indomethacin (group 1, n = 73) or ibuprofen (group 2, n = 49) and those without symptomatic pericarditis received neither drug (group 3, n = 99)." | 8.77 | Myocardial infarct expansion during indomethacin or ibuprofen therapy for symptomatic post infarction pericarditis. Influence of other pharmacologic agents during early remodelling. ( Basualdo, CA; Jugdutt, BI, 1989) |
| "The aim was to assess whether using LSPS matching would enable the evaluation of paracetamol, compared to ibuprofen, and increased risk of myocardial infarction, stroke, gastrointestinal (GI) bleeding, or acute renal failure." | 7.96 | Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen. ( Berlin, JA; Fife, D; Ryan, PB; Schuemie, MJ; Swerdel, J; Weinstein, RB, 2020) |
| "To determine whether patients taking aspirin for secondary prevention of myocardial infarction are at increased risk of recurrent disease when they take concomitant ibuprofen." | 7.73 | Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. ( Baron, M; Hudson, M; Pilote, L; Rahme, E, 2005) |
| "This study was designed to determine if non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) are associated with lower odds of myocardial infarction (MI) and if NANSAIDs, particularly ibuprofen, interfere with aspirin's cardioprotective effect." | 7.72 | The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2004) |
| "There does not seem to be an increased risk of myocardial infarction among patients simultaneously consuming aspirin and ibuprofen compared with aspirin alone." | 7.72 | Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. ( Goldberg, KC; Patel, TN, 2004) |
| "To assess the ability of ibuprofen to influence the extent of platelet aggregation and leukocyte infiltration during acute myocardial infarction, autologous indium-111 (111-In)-labeled platelets or leukocytes were injected before 60 minutes of left circumflex coronary artery (LCx) occlusion, followed by 24 hours of reperfusion in the canine heart." | 7.66 | The effect of ibuprofen on accumulation of indium-111-labeled platelets and leukocytes in experimental myocardial infarction. ( Hook, BG; Lucchesi, BR; Rigot, VH; Romson, JL; Schork, MA; Swanson, DP, 1982) |
| "Pre-treatment with ibuprofen (30, 60 and 90mg/kg p." | 5.43 | Inhibition of RhoA/Rho kinase by ibuprofen exerts cardioprotective effect on isoproterenol induced myocardial infarction in rats. ( Gandhi, T; Parikh, M; Patel, P; Shah, H, 2016) |
| "Celecoxib and rofecoxib were associated with different odds of MI." | 5.33 | Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2005) |
| " Patients with symptomatic pericarditis were treated with indomethacin (group 1, n = 73) or ibuprofen (group 2, n = 49) and those without symptomatic pericarditis received neither drug (group 3, n = 99)." | 4.77 | Myocardial infarct expansion during indomethacin or ibuprofen therapy for symptomatic post infarction pericarditis. Influence of other pharmacologic agents during early remodelling. ( Basualdo, CA; Jugdutt, BI, 1989) |
| "In parallel with experimental research into methods for salvage of ischemic myocardium after acute myocardial infarction (AMI) over the last decade, there has been a growing interest in prostaglandins (PG) and their inhibition by aspirin-like drugs or nonsteroidal anti-inflammatory drugs (NSAID)." | 4.76 | Prostaglandin inhibition and myocardial infarct size. ( Becker, LC; Jugdutt, BI, 1981) |
| " We used a Mantel-Haenszel method to obtain odds ratios (ORs) of the association between NSAID use (ibuprofen, naproxen, or diclofenac) and MACE (myocardial infarction, ischemic stroke, heart failure, or all-cause death)." | 4.31 | Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study. ( Bonnesen, K; Ehrenstein, V; Grønkjær, MS; Hallas, J; Lash, TL; Pedersen, L; Schmidt, M; Sørensen, HT, 2023) |
| " After applying these weights in a pooled logistic regression, we estimated hazard ratios (HRs) of the association between use of NSAIDs (ibuprofen, naproxen, or diclofenac) and cardiovascular events (a composite of myocardial infarction, ischemic stroke, congestive heart failure, atrial fibrillation or flutter, and all-cause death)." | 4.31 | Impact of hemoglobin A1c level on the association between non-steroidal anti-inflammatory drug use and cardiovascular events in patients with type 2 diabetes: A population-based cohort study. ( Bonnesen, K; Ehrenstein, V; Lash, TL; Pedersen, L; Schmidt, M; Sørensen, HT, 2023) |
| "The aim was to assess whether using LSPS matching would enable the evaluation of paracetamol, compared to ibuprofen, and increased risk of myocardial infarction, stroke, gastrointestinal (GI) bleeding, or acute renal failure." | 3.96 | Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen. ( Berlin, JA; Fife, D; Ryan, PB; Schuemie, MJ; Swerdel, J; Weinstein, RB, 2020) |
| "This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease." | 3.77 | Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011) |
| " Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0." | 3.75 | Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009) |
| "To investigate the risk of myocardial infarction (MI) with diclofenac, ibuprofen and naproxen, taking into account the exposure patterns." | 3.74 | Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? ( Leufkens, HG; Rietbrock, S; Setakis, E; van Staa, TP, 2008) |
| "To evaluate the association between rofecoxib, celecoxib, diclofenac, and ibuprofen and the risk of hospitalization for acute myocardial infarction (AMI) in an elderly population." | 3.74 | Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. ( Kong, SX; LeLorier, J; Rahme, E; Toubouti, Y; Watson, DJ, 2007) |
| "To determine whether patients taking aspirin for secondary prevention of myocardial infarction are at increased risk of recurrent disease when they take concomitant ibuprofen." | 3.73 | Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. ( Baron, M; Hudson, M; Pilote, L; Rahme, E, 2005) |
| "To simultaneously assess the short-term reduction in risk of gastrointestinal (GI) complications and increase in risk of acute myocardial infarction (MI) by celecoxib compared with rofecoxib and several nonselective nonsteroidal antiinflammatory drugs (NSAIDs) using instrumental variable analysis." | 3.73 | Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. ( Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS, 2006) |
| "Patients suffering an acute myocardial infarction routinely receive morphine and nonsteroidal anti-inflammatory drugs (NSAIDs) alone or in combination." | 3.72 | Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase. ( Gross, ER; Gross, GJ; Hsu, AK, 2004) |
| "This study was designed to determine if non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) are associated with lower odds of myocardial infarction (MI) and if NANSAIDs, particularly ibuprofen, interfere with aspirin's cardioprotective effect." | 3.72 | The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2004) |
| "There does not seem to be an increased risk of myocardial infarction among patients simultaneously consuming aspirin and ibuprofen compared with aspirin alone." | 3.72 | Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. ( Goldberg, KC; Patel, TN, 2004) |
| "Non-aspirin, non-steroidal anti-inflammatory drugs (NANSAIDs) have complex effects that could either prevent or promote coronary heart disease." | 3.71 | Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. ( Daugherty, JR; Griffin, MR; Hall, K; Ray, WA; Stein, CM, 2002) |
| "The prophylactic role of ibuprofen in experimental myocardial infarction has not been reported." | 3.68 | Failure to reduce experimental myocardial infarct size with ibuprofen pre-treatment in rats. ( Lal, A; Sharma, ML, 1992) |
| "To assess the ability of ibuprofen to influence the extent of platelet aggregation and leukocyte infiltration during acute myocardial infarction, autologous indium-111 (111-In)-labeled platelets or leukocytes were injected before 60 minutes of left circumflex coronary artery (LCx) occlusion, followed by 24 hours of reperfusion in the canine heart." | 3.66 | The effect of ibuprofen on accumulation of indium-111-labeled platelets and leukocytes in experimental myocardial infarction. ( Hook, BG; Lucchesi, BR; Rigot, VH; Romson, JL; Schork, MA; Swanson, DP, 1982) |
| " An increased risk was observed for diclofenac and rofecoxib, the latter one with a clear dose-response trend." | 2.43 | Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. ( García Rodríguez, LA; Hernández-Díaz, S; Varas-Lorenzo, C, 2006) |
| "Pre-treatment with ibuprofen (30, 60 and 90mg/kg p." | 1.43 | Inhibition of RhoA/Rho kinase by ibuprofen exerts cardioprotective effect on isoproterenol induced myocardial infarction in rats. ( Gandhi, T; Parikh, M; Patel, P; Shah, H, 2016) |
| "Celecoxib and rofecoxib were associated with different odds of MI." | 1.33 | Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2005) |
| "Naproxen was associated with an OR of 0." | 1.32 | Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. ( García Rodríguez, LA; González-Pérez, A; Maguire, A; Varas-Lorenzo, C, 2004) |
| "1." | 1.29 | Dissociation of the anti-ischaemic effects of cloricromene from its anti-platelet activity. ( Cirillo, R; Lidbury, PS; Vane, JR, 1993) |
| "Ibuprofen and verapamil treatment resulted in less myocardial damage after 48 h than placebo treatment but the differences were generally not statistically significant." | 1.27 | Evaluation of a rat model for assessing interventions to salvage ischaemic myocardium: effects of ibuprofen and verapamil. ( Evans, RG; Fischer, VW; Kulevich, J; Mueller, HS; Val-Mejias, JE, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (36.51) | 18.7374 |
| 1990's | 4 (6.35) | 18.2507 |
| 2000's | 25 (39.68) | 29.6817 |
| 2010's | 6 (9.52) | 24.3611 |
| 2020's | 5 (7.94) | 2.80 |
| Authors | Studies |
|---|---|
| Baak, BN | 1 |
| Jick, SS | 1 |
| Bonnesen, K | 2 |
| Pedersen, L | 2 |
| Ehrenstein, V | 2 |
| Grønkjær, MS | 1 |
| Sørensen, HT | 2 |
| Hallas, J | 2 |
| Lash, TL | 2 |
| Schmidt, M | 3 |
| Ernst, MT | 1 |
| Pottegård, A | 1 |
| Weinstein, RB | 1 |
| Ryan, PB | 1 |
| Berlin, JA | 3 |
| Schuemie, MJ | 1 |
| Swerdel, J | 1 |
| Fife, D | 1 |
| Chen, YR | 1 |
| Hsieh, FI | 1 |
| Chang, CC | 1 |
| Chi, NF | 1 |
| Wu, HC | 1 |
| Chiou, HY | 1 |
| Bhala, N | 1 |
| Emberson, J | 1 |
| Merhi, A | 1 |
| Abramson, S | 1 |
| Arber, N | 1 |
| Baron, JA | 1 |
| Bombardier, C | 1 |
| Cannon, C | 1 |
| Farkouh, ME | 1 |
| FitzGerald, GA | 1 |
| Goss, P | 1 |
| Halls, H | 1 |
| Hawk, E | 1 |
| Hawkey, C | 1 |
| Hennekens, C | 1 |
| Hochberg, M | 1 |
| Holland, LE | 1 |
| Kearney, PM | 1 |
| Laine, L | 1 |
| Lanas, A | 1 |
| Lance, P | 1 |
| Laupacis, A | 1 |
| Oates, J | 1 |
| Patrono, C | 1 |
| Schnitzer, TJ | 1 |
| Solomon, S | 1 |
| Tugwell, P | 1 |
| Wilson, K | 1 |
| Wittes, J | 1 |
| Baigent, C | 1 |
| Patel, P | 1 |
| Parikh, M | 1 |
| Shah, H | 1 |
| Gandhi, T | 1 |
| van Staa, TP | 1 |
| Rietbrock, S | 1 |
| Setakis, E | 1 |
| Leufkens, HG | 1 |
| Ray, WA | 2 |
| Varas-Lorenzo, C | 3 |
| Chung, CP | 1 |
| Castellsague, J | 1 |
| Murray, KT | 1 |
| Stein, CM | 2 |
| Daugherty, JR | 2 |
| Arbogast, PG | 1 |
| García-Rodríguez, LA | 1 |
| Schjerning Olsen, AM | 1 |
| Fosbøl, EL | 1 |
| Lindhardsen, J | 1 |
| Folke, F | 1 |
| Charlot, M | 1 |
| Selmer, C | 1 |
| Lamberts, M | 1 |
| Bjerring Olesen, J | 1 |
| Køber, L | 2 |
| Hansen, PR | 1 |
| Torp-Pedersen, C | 2 |
| Gislason, GH | 2 |
| Bavry, AA | 1 |
| Khaliq, A | 1 |
| Gong, Y | 1 |
| Handberg, EM | 1 |
| Cooper-Dehoff, RM | 1 |
| Pepine, CJ | 1 |
| He, B | 1 |
| Tang, J | 1 |
| Ding, Y | 1 |
| Wang, H | 1 |
| Sun, Y | 1 |
| Shin, JH | 1 |
| Chen, B | 1 |
| Moorthy, G | 1 |
| Qiu, J | 1 |
| Desai, P | 1 |
| Wild, DJ | 1 |
| Brandt, KD | 1 |
| Kimmel, SE | 3 |
| Strom, BL | 3 |
| Curtis, JP | 2 |
| Wang, Y | 1 |
| Portnay, EL | 1 |
| Masoudi, FA | 1 |
| Havranek, EP | 1 |
| Krumholz, HM | 2 |
| Gross, ER | 1 |
| Hsu, AK | 1 |
| Gross, GJ | 1 |
| Reilly, M | 2 |
| Jaskowiak, J | 2 |
| Kishel, L | 2 |
| Chittams, J | 2 |
| Patel, TN | 1 |
| Goldberg, KC | 1 |
| García Rodríguez, LA | 2 |
| Maguire, A | 1 |
| González-Pérez, A | 1 |
| Lee, RT | 1 |
| Hudson, M | 1 |
| Baron, M | 1 |
| Rahme, E | 2 |
| Pilote, L | 1 |
| Hernández-Díaz, S | 1 |
| Jacobsen, S | 1 |
| Rasmussen, JN | 1 |
| Rasmussen, S | 1 |
| Buch, P | 1 |
| Friberg, J | 1 |
| Schramm, TK | 1 |
| Abildstrom, SZ | 1 |
| Madsen, M | 1 |
| Schneeweiss, S | 1 |
| Solomon, DH | 1 |
| Wang, PS | 1 |
| Rassen, J | 1 |
| Brookhart, MA | 1 |
| Watson, DJ | 1 |
| Kong, SX | 1 |
| Toubouti, Y | 1 |
| LeLorier, J | 1 |
| Singh, H | 1 |
| Hennekens, CH | 1 |
| Borzak, S | 1 |
| Flynn, PJ | 1 |
| Becker, WK | 1 |
| Vercellotti, GM | 1 |
| Weisdorf, DJ | 1 |
| Craddock, PR | 1 |
| Hammerschmidt, DE | 1 |
| Lillehei, RC | 1 |
| Jacob, HS | 1 |
| Huval, WV | 1 |
| Lelcuk, S | 1 |
| Allen, PD | 1 |
| Mannick, JA | 1 |
| Shepro, D | 1 |
| Hechtman, HB | 1 |
| Jugdutt, BI | 6 |
| Brown, EJ | 1 |
| Kloner, RA | 2 |
| Schoen, FJ | 1 |
| Hammerman, H | 1 |
| Hale, S | 1 |
| Braunwald, E | 1 |
| Becker, LC | 3 |
| Kirlin, PC | 1 |
| Romson, JL | 3 |
| Pitt, B | 1 |
| Abrams, GD | 1 |
| Schork, MA | 2 |
| Lucchesi, BR | 3 |
| Hook, BG | 1 |
| Rigot, VH | 1 |
| Swanson, DP | 1 |
| Darsee, JR | 1 |
| Lefer, AM | 1 |
| Crossley, K | 1 |
| Hutchins, GM | 2 |
| Bulkley, BH | 2 |
| Maroko, PR | 1 |
| Lidbury, PS | 1 |
| Cirillo, R | 1 |
| Vane, JR | 1 |
| Schafer, A | 1 |
| Hall, K | 1 |
| Griffin, MR | 1 |
| Miser, WF | 1 |
| Lal, A | 1 |
| Sharma, ML | 1 |
| Bailey, KR | 2 |
| Sinitsyn, SP | 1 |
| Basualdo, CA | 1 |
| Przyklenk, K | 1 |
| Hess, ML | 1 |
| Rowe, GT | 1 |
| Caplan, M | 1 |
| Lucchesi, B | 1 |
| Reimer, KA | 1 |
| Jennings, RB | 1 |
| Cobb, FR | 1 |
| Murdock, RH | 1 |
| Greenfield, JC | 1 |
| Schwartz, RP | 1 |
| Spodick, DH | 1 |
| Hasselstrøm, LJ | 1 |
| Eliasen, K | 1 |
| Mogensen, T | 1 |
| Andersen, JB | 1 |
| Evans, RG | 1 |
| Val-Mejias, JE | 1 |
| Kulevich, J | 1 |
| Fischer, VW | 1 |
| Mueller, HS | 1 |
| Cannon, RO | 1 |
| Rodríguez, ER | 1 |
| Speir, E | 1 |
| Yamaguchi, M | 1 |
| Butany, J | 1 |
| McManus, BM | 1 |
| Bolli, R | 1 |
| Ferrans, VJ | 1 |
| Boden, WE | 1 |
| Sadaniantz, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators[NCT03664466] | 0 participants (Actual) | Interventional | 2021-04-29 | Withdrawn (stopped due to Inadequate funding) | |||
| Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration[NCT02380001] | Phase 4 | 60 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.[NCT01910116] | Phase 2/Phase 3 | 220 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effects on Omission of NSAIDs on the Consumption of Opioids in the Standard Analgesic Regimen After Elective Laparoscopic Colorectal Cancer Resection in an ERAS Setting. A Retrospective Single-center Cohort Study.[NCT04448652] | 502 participants (Actual) | Observational [Patient Registry] | 2015-01-01 | Completed | |||
| A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| Single and Repeated Leech Therapy for the Treatment of Late Stage Knee Osteoarthritis. A Randomized, Placebo Controlled Comparative Trial[NCT00435773] | Phase 2 | 118 participants | Interventional | 2004-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11 |
| Placebo | -2.9 |
"Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.9 |
| Placebo | -4.8 |
"Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -6.8 |
| Placebo | -3.7 |
"Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.7 |
| Placebo | -4.8 |
"Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).~AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -2.2 |
"Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.6 |
| Placebo | -8.0 |
"Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -15.6 |
| Placebo | -4.4 |
"Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -13.4 |
| Placebo | -2.2 |
"Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.0 |
| Placebo | -11.0 |
"Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.0 |
"Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -6.0 |
"Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12.0 |
| Placebo | -6 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baselie and 16 weeks
| Intervention | participants (Number) |
|---|---|
| Shinbaro | 55 |
| Placebo | 40 |
"Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11.0 |
| Placebo | -6.0 |
"Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.5 |
"Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -3.0 |
"Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -6.0 |
"Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -19.0 |
| Placebo | -13 |
"Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -6.5 |
"Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -7.0 |
"Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -16.0 |
| Placebo | -11.5 |
"Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -1 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | -1.0 |
| Placebo | -1.0 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 12 weeks and 16 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 2 | 104 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 4 weeks and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 7 | 99 |
| Shinbaro | 10 | 99 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 8 weeks and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: Baseline 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 7 | 102 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 43 | 63 |
| Shinbaro | 62 | 47 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 38 | 68 |
| Shinbaro | 56 | 53 |
Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Nonresponder | |
| Placebo | 32 | 74 |
| Shinbaro | 48 | 61 |
5 reviews available for ibuprofen and Cardiovascular Stroke
| Article | Year |
|---|---|
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cohort Studies; Diclofenac; Dose-Resp | 2006 |
Prostaglandin inhibition and myocardial infarct size.
Topics: Acute Disease; Animals; Aspirin; Coronary Disease; Humans; Ibuprofen; Indomethacin; Models, Biologic | 1981 |
Myocardial ischemia, reperfusion and free radical injury.
Topics: Animals; Cell Adhesion Molecules; Chemotactic Factors; Complement Activation; E-Selectin; Free Radic | 1990 |
Myocardial infarct expansion during indomethacin or ibuprofen therapy for symptomatic post infarction pericarditis. Influence of other pharmacologic agents during early remodelling.
Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Echocardiography; Ibuprofen; Indomethacin; | 1989 |
1 trial available for ibuprofen and Cardiovascular Stroke
| Article | Year |
|---|---|
Determinants of cardiovascular stability during abdominal aortic aneurysmectomy (AAA).
Topics: Aged; Aorta, Abdominal; Aortic Aneurysm; Blood Platelets; Epoprostenol; Female; Heart; Hematologic T | 1984 |
57 other studies available for ibuprofen and Cardiovascular Stroke
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs and risk of myocardial infarction adjusting for use of proton pump-inhibitors in patients with no major risk factors: a nested case-control study in the UK Clinical Practice Research Datalink.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclofenac; Humans; Ibuprofen; Myocar | 2022 |
Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cross-Over Studies; Diclofe | 2023 |
Impact of hemoglobin A1c level on the association between non-steroidal anti-inflammatory drug use and cardiovascular events in patients with type 2 diabetes: A population-based cohort study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Diabetes Mellitus, Type 2; Diclofena | 2023 |
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cohort Studies; Diclofenac; Heart | 2023 |
Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen.
Topics: Acetaminophen; Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Ag | 2020 |
Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2018 |
Inhibition of RhoA/Rho kinase by ibuprofen exerts cardioprotective effect on isoproterenol induced myocardial infarction in rats.
Topics: Animals; Antioxidants; Cardiotonic Agents; Electrocardiography; Gene Expression Regulation, Enzymolo | 2016 |
Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dr | 2008 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C | 2009 |
Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cohor | 2011 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec | 2011 |
Mining relational paths in integrated biomedical data.
Topics: Algorithms; Computers; Data Collection; Data Mining; Databases, Factual; Humans; Hypoglycemic Agents | 2011 |
Key questions concerning paracetamol and NSAIDs for OA.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; I | 2003 |
Giving aspirin and ibuprofen after myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Drug Interactions; Humans; Ibup | 2003 |
Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Contraindications; Drug Inte | 2003 |
Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 12-Lipoxygenase; Aspirin; Blood Press | 2004 |
The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Drug Interactio | 2004 |
The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: is it time to believe the hype?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I | 2004 |
Painkillers appear to weaken aspirin's primary protection.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I | 2003 |
Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Female; Humans; I | 2004 |
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Case- | 2004 |
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confo | 2005 |
Ask the doctor. I am a 60-year-old man with several risk factors for heart disease. I take Aleve twice a day. Do I still need to take aspirin, or is the Aleve enough? I often take ibuprofen for my headaches or aching back. Now my doctor wants me to start
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Drug Interactions; Huma | 2005 |
Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Contraindications; Drug Inte | 2005 |
[Study results of routine clinical practice. Do rheumatism patients get substandard care?].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; | 2005 |
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Confidence Intervals; C | 2006 |
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; F | 2006 |
Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Stu | 2007 |
Take aspirin before ibuprofen, not after.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Drug Interactions; H | 2006 |
Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dicl | 2007 |
Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy | 2008 |
Ibuprofen inhibits granulocyte responses to inflammatory mediators. A proposed mechanism for reduction of experimental myocardial infarct size.
Topics: Animals; Aspirin; Cats; Complement C5; Coronary Vessels; Female; Granulocytes; Ibuprofen; Ligation; | 1984 |
Effect of PGE1, PGE2 and PGI2 on ventricular arrhythmias during myocardial infarction in conscious dogs: relation to infarct size.
Topics: Alprostadil; Animals; Arrhythmias, Cardiac; Collateral Circulation; Dinoprostone; Dogs; Electrocardi | 1981 |
Scar thinning due to ibuprofen administration after experimental myocardial infarction.
Topics: Animals; Aspirin; Dogs; Female; Hydroxyproline; Ibuprofen; Male; Myocardial Infarction; Myocardium | 1983 |
Ibuprofen-mediated infarct size reduction: effects on regional myocardial function in canine myocardial infarction in canine myocardial infarction.
Topics: Animals; Arterial Occlusive Diseases; Blood Pressure; Coronary Disease; Dogs; Heart Rate; Ibuprofen; | 1982 |
The effect of ibuprofen on accumulation of indium-111-labeled platelets and leukocytes in experimental myocardial infarction.
Topics: Animals; Blood Platelets; Dogs; Ibuprofen; Indium; Inflammation; Isotope Labeling; Leukocytes; Myoca | 1982 |
Dependency of location of salvageable myocardium on type of intervention.
Topics: Animals; Coronary Circulation; Coronary Disease; Dogs; Female; Flurbiprofen; Glycine; Heart; Ibuprof | 1981 |
Mechanisms of the optimal protective effects of ibuprofen in acute myocardial ischemia.
Topics: Animals; Blood Pressure; Cats; Central Venous Pressure; Coronary Vessels; Female; Heart Rate; Ibupro | 1980 |
Salvage of ischemic myocardium by ibuprofen during infarction in the conscious dog.
Topics: Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Dogs; Electrocardiography; Heart Ra | 1980 |
Experimental infarction studies.
Topics: Animals; Chlorpromazine; Dogs; Heart Rate; Ibuprofen; Morphine; Myocardial Infarction; Myocardium; P | 1980 |
Dissociation of the anti-ischaemic effects of cloricromene from its anti-platelet activity.
Topics: Animals; Blood Pressure; Chromonar; Coronary Vessels; Electrocardiography; Heart Rate; Ibuprofen; In | 1993 |
My doctor recently recommended that I take low-dose aspirin to minimize the risk of a heart attack or stroke. I routinely take ibuprofen for arthritis pain. Do I need both, and is it safe to combine the two?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I | 2000 |
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.
Topics: Age Distribution; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; C | 2002 |
An aspirin a day keeps the MI away (for some).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Antagonism; H | 2002 |
Failure to reduce experimental myocardial infarct size with ibuprofen pre-treatment in rats.
Topics: Animals; Female; Heart; Ibuprofen; Isoproterenol; Male; Myocardial Infarction; Myocardium; Rats | 1992 |
Detecting fabrication of data in a multicenter collaborative animal study.
Topics: Animals; Data Interpretation, Statistical; Disease Models, Animal; Dogs; Ibuprofen; Multicenter Stud | 1991 |
[Correction of metabolic disorders of the myocardium in acute myocardial infarct as an important factor in preventing the development of circulatory insufficiency].
Topics: Animals; Aprotinin; Ascorbic Acid; Drug Therapy, Combination; Glutamates; Glutamic Acid; Heart Failu | 1985 |
Effect of chronic ibuprofen therapy on early healing of experimentally induced acute myocardial infarction in dogs.
Topics: Animals; Collagen; Dogs; Drug Administration Schedule; Ibuprofen; Myocardial Infarction; Myocardium; | 1989 |
Identification of hydrogen peroxide and hydroxyl radicals as mediators of leukocyte-induced myocardial dysfunction. Limitation of infarct size with neutrophil inhibition and depletion.
Topics: Adenosine Triphosphatases; Animals; Butylated Hydroxytoluene; Calcium; Catalase; Dogs; Free Radicals | 1985 |
Effect of nitroglycerin and ibuprofen on left ventricular topography and rupture threshold during healing after myocardial infarction in the dog.
Topics: Animals; Dogs; Echocardiography; Heart; Heart Rupture; Hemodynamics; Hydroxyproline; Ibuprofen; Myoc | 1988 |
Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models.
Topics: Anesthesia; Animal Testing Alternatives; Animals; Arterial Occlusive Diseases; Coronary Circulation; | 1985 |
Delayed effects of early infarct-limiting therapies on healing after myocardial infarction.
Topics: Animals; Collagen; Dogs; Epoprostenol; Hemodynamics; Hydroxyproline; Ibuprofen; Macrophages; Myocard | 1985 |
Safety of ibuprofen for acute myocardial infarction pericarditis.
Topics: Humans; Ibuprofen; Myocardial Infarction; Pericarditis | 1986 |
Lowering pulmonary artery pressure in a patient with severe acute respiratory failure.
Topics: Blood Pressure; Humans; Hypertension, Pulmonary; Ibuprofen; Male; Middle Aged; Myocardial Infarction | 1985 |
Evaluation of a rat model for assessing interventions to salvage ischaemic myocardium: effects of ibuprofen and verapamil.
Topics: Animals; Body Weight; Creatine Kinase; Disease Models, Animal; Ibuprofen; Male; Myocardial Infarctio | 1985 |
Effect of ibuprofen on the healing phase of experimental myocardial infarction in the rat.
Topics: Animals; Cell Count; Collagen; Hydroxyproline; Ibuprofen; Leukocytes; Male; Myocardial Infarction; R | 1985 |
Ventricular septal rupture during ibuprofen therapy for pericarditis after acute myocardial infarction.
Topics: Aged; Female; Heart Rupture; Heart Septum; Humans; Ibuprofen; Male; Middle Aged; Myocardial Infarcti | 1985 |